TEK and cerebral cavernous malformation: To determine if inhibition of Tie2 could be used as therapeutics for CCM, we tested the effects of Tie2 inhibitor Rebastinib (DCC-2036), a phase 1b/phase 2 clinical trial drug, and selective Tie2 kinase inhibitor, in the Ccm3 mouse models.